Glioblastoma multiforme is an aggressive type of brain cancer. Credit: KGH.

WPD Pharmaceuticals has reported positive data from the Phase I clinical trial of Berubicin drug to treat glioblastoma multiforme (GBM).

The clinical trial of Berubicin drug, conducted by pharmaceutical company Reata Pharmaceuticals, found that a patient remained cancer-free.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

At present, no approved effective therapies are available to treat GBM, an aggressive type of brain cancer.

WPD Pharmaceuticals CEO Mariusz Olejniczak said: “We are delighted to provide this update on Berubicin’s potential capabilities as we continue to develop the drug. We are very encouraged by these results and remain hopeful in our efforts to treat glioblastoma multiforme.

“We are looking forward to initiating the Phase II clinical trial in the second half of this year with our partner, CNS Pharmaceuticals.”

In the Phase I trial of the drug, 44% of patients reported a statistically significant improvement in progression-free survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Disease control rate comes from 11 out of 25 evaluable patients with stable disease, plus responders.

During the trial, one patient experienced a durable complete response, defined as the disappearance of all signs of cancer in response to treatment, by the National Cancer Institute.

The initial trial took place in 2006, and the patient has remained cancer-free for over 13 years, as of February.

Last month, WPD Pharmaceuticals and CNS Pharmaceuticals announced plans to initiate a Phase I clinical trial for Berubicin, an anthracycline, in paediatric brain cancer at the Children’s Memorial Health Institute in Poland.

WPD has ten novel drug candidates, and four of them are in the clinical development stage.